Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
230 hedge funds and large institutions have $3.26B invested in Sage Therapeutics in 2020 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 72 increasing their positions, 75 reducing their positions, and 25 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
121% more call options, than puts
Call options by funds: $59.6M | Put options by funds: $27M
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
45% more capital invested
Capital invested by funds: $2.25B → $3.26B (+$1.01B)
6% more funds holding
Funds holding: 216 → 230 (+14)
0.81% less ownership
Funds ownership: 104.05% → 103.25% (-0.81%)
4% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$47.7M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$21.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$17.3M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.7M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$31.9M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$21.8M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$18.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.2M |
| 5 |
Two Sigma Investments
New York
|
-$15.4M |
SAGE Hedge Fund Activity: Q3 2020 in Review
230 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2020, worth a combined $3.26B — up 45% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SAGE positions and 25 closed out — a net gain of 14 holders — while 72 added to existing stakes and 75 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $47.7M. The largest seller was State Street, cutting an estimated $31.9M.
- 230 institutional investors held Sage Therapeutics (SAGE) as of Q3 2020, up from 216 in Q2 2020.
- Funds reported $3.26B of Sage Therapeutics stock for Q3 2020, up 45% quarter-over-quarter.
- 39 funds opened new Sage Therapeutics positions in Q3 2020 and 25 closed out, a net change of +14 holders.
- The largest Sage Therapeutics buyer in Q3 2020 was Adage Capital Partners, an estimated $47.7M added.
- The largest Sage Therapeutics seller in Q3 2020 was State Street, an estimated $31.9M sold.
Based on aggregated 13F filings for Q3 2020.